Efficient phagocytosis and laccase activity affect the outcome of HIV-associated cryptococcosis

Journal of Clinical Investigation

Volumn 124, Issue 5, 2014, Pages 2000-2008

  Sabiiti, Wilber ^a,b,c   Robertson, Emma ^a   Beale, Mathew A ^a,d   Johnston, Simon A ^e,f   Brouwer, Annemarie E ^g   Loyse, Angela ^a   Jarvis, Joseph N ^h   Gilbert, Andrew S ^b   Fisher, Matthew C ^d   Harrison, Thomas S ^a   May, Robin C ^b,i   Bicanic, Tihana ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF ST ANDREWS   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

^f UNIVERSITY OF SHEFFIELD   (United Kingdom)

^g CPRLab   (Netherlands)

^h LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

ⁱ QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; LACCASE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MELANIN; MONOCYTE CHEMOTACTIC PROTEIN 1; OPSONIN; RANTES; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; ARTICLE; CELL PROLIFERATION; CELL WALL; CELLULAR PARAMETERS; CEREBROSPINAL FLUID; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS NEOFORMANS; ENZYME ACTIVITY; FEMALE; FOLLOW UP; FUNGAL BURDEN; FUNGAL STRAIN; FUNGAL VIRULENCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS ASSOCIATED CRYPTOCOCCOSIS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRACELLULAR PROLIFERATION RATE; LEUKOCYTE COUNT; LONG TERM SURVIVAL; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MELANOGENESIS; MICROBIAL DIVERSITY; OUTCOME ASSESSMENT; PATHOGEN LOAD; PHAGOCYTE; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; CELL LINE; CRYPTOCOCCUS NEOFORMANS; FEMALE; HUMANS; LACCASE; MACROPHAGES; MALE; MENINGITIS, CRYPTOCOCCAL; MICE; PHAGOCYTOSIS; SURVIVAL RATE;

EID: 84899712756     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI72950     Document Type: Article

References (42)

1. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23(4):525-530.
2. Jarvis JN, et al. High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. AIDS. 2009;23(9):1182-1183.
3. Loyse A, et al. Cryptococcal meningitis: improving access to essential antifungal medicines in resourcepoor countries. Lancet Infect Dis. 2013;13(7):629-637.
4. Brouwer AE, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet. 2004;363(9423):1764-1767.
5. Day JN, et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med. 2013; 368(14):1291-1302.
6. Saag MS, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med. 1992;326(2):83-89.
7. Jarvis JN, Harrison TS. HIV-associated cryptococcal meningitis. AIDS. 2007;21(16):2119-2129.
8. Bicanic T, et al. Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis. 2009;49(5):702-709.
9. Jarvis JN, Harrison TS. Pulmonary cryptococcosis. Semin Respir Crit Care Med. 2008;29(2):141-150.
10. Sabiiti W, May RC. Mechanisms of infection by the human fungal pathogen Cryptococcus neoformans. Future Microbiol. 2012;7(11):1297-1313.
11. Jarvis JN, et al. The phenotype of the Cryptococcus- specific CD4+ memory T-cell response is associated with disease severity and outcome in HIV-associated cryptococcal meningitis. J Infect Dis. 2013;207(12):1817-1828.
12. Siddiqui AA, et al. IFN- at the site of infection determines rate of clearance of infection in cryptococcal meningitis. J Immunol. 2005;174(3):1746-1750.
13. Wiesner DL, et al. Cryptococcal genotype influences immunologic response and human clinical outcome after meningitis. MBio. 2012;3(5):e00196-12.
14. Alanio A, Desnos-Ollivier M, Dromer F. Dynamics of Cryptococcus neoformans-macrophage interactions reveal that fungal background influences outcome during cryptococcal meningoencephalitis in humans. MBio. 2011;2(4):e00158-11.
15. Ma H, May RC. Virulence in Cryptococcus species. Adv Appl Microbiol. 2009;67:131-190.
16. Ma H, et al. The fatal fungal outbreak on Vancouver Island is characterized by enhanced intracellular parasitism driven by mitochondrial regulation. Proc Natl Acad Sci U S A. 2009;106(31):12980-12985.
17. Garcia-Rodas R, Zaragoza O. Catch me if you can: phagocytosis and killing avoidance by Cryptococcus neoformans. FEMS Immunol Med Microbiol. 2012;64(2):147-161.
18. Robertson EJ, et al. Cryptococcus neoformans ex vivo capsule size is associated with intracranial pressure and host immune response in HIV-associated cryptococcal meningitis. J Infect Dis. 2014;209(1):74-82.
19. Zhu X, Williamson PR.Role of laccase in the biology and virulence of Cryptococcus neoformans. FEMS Yeast Res. 2004;5(1):1-10.
20. Erb-Downward JR, Noggle RM, Williamson PR, Huffnagle GB. The role of laccase in prostaglandin production by Cryptococcus neoformans. Mol Microbiol. 2008;68(6):1428-1437.
21. Wang Y, Aisen P, Casadevall A. Melanin, melanin "ghosts," and melanin composition in Cryptococcus neoformans. Infect Immun. 1996;64(7):2420-2424.
22. Bicanic T, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis. 2007;45(1):76-80.
23. Bicanic T, et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis. 2008;47(1):123-130.
24. Loyse A, et al. Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis. 2012;54(1):121-128.
25. Jarvis JN, et al. Adjunctive interferon- immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS. 2012;26(9):1105-1113.
26. Rohatgi S, et al. Fc receptor 3A polymorphism and risk for HIV-associated cryptococcal disease. MBio. 2013;4(5):e00573-13.
27. Ma H, Croudace JE, Lammas DA, May RC. Expulsion of live pathogenic yeast by macrophages. Curr Biol. 2006;16(21):2156-2160.
28. Alvarez M, Casadevall A. Phagosome extrusion and host-cell survival after Cryptococcus neoformans phagocytosis by macrophages. Curr Biol. 2006;16(21):2161-2165.
29. Ma H, Croudace JE, Lammas DA, May RC. Direct cell-to-cell spread of a pathogenic yeast. BMC Immunol. 2007;8:15.
30. Nicola AM, Robertson EJ, Albuquerque P, Derengowski Lda S, Casadevall A. Nonlytic exocytosis of Cryptococcus neoformans from macrophages occurs in vivo and is influenced by phagosomal pH. MBio. 2011;2(4):e00167-11.
31. Chretien F, Lortholary O, Kansau I, Neuville S, Gray F, Dromer F. Pathogenesis of cerebral Cryptococcus neoformans infection after fungemia. J Infect Dis. 2002;186(4):522-530.
32. Charlier C, Nielsen K, Daou S, Brigitte M, Chretien F, Dromer F. Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans. Infect Immun. 2009;77(1):120-127.
33. Ikeda R, Sugita T, Jacobson ES, Shinoda T. Effects of melanin upon susceptibility of Cryptococcus to antifungals. Microbiol Immunol. 2003;47(4):271-277.
34. van Duin D, Casadevall A, Nosanchuk JD. Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin. Antimicrob Agents Chemother. 2002;46(11):3394-3400.
35. Wang Y, Casadevall A. Growth of Cryptococcus neoformans in presence of L-dopa decreases its susceptibility to amphotericin B. Antimicrob Agents Chemother. 1994;38(11):2648-2650.
36. Kwon-Chung KJ, Tom WK, Costa JL. Utilization of indole compounds by Cryptococcus neoformans to produce a melanin-like pigment. J Clin Microbiol. 1983;18(6):1419-1421.
37. Lee SC, Dickson DW, Casadevall A. Pathology of cryptococcal meningoencephalitis: analysis of 27 patients with pathogenetic implications. Hum Pathol. 1996;27(8):839-847.
38. Nosanchuk JD, Rosas AL, Lee SC, Casadevall A. Melanisation of Cryptococcus neoformans in human brain tissue. Lancet. 2000;355(9220):2049-2050.
39. Mesa-Arango AC, Scorzoni L, Zaragoza O. It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug. Front Microbiol. 2012;3:286.
40. Meyer W, et al. Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med Mycol. 2009;47(6):561-570.
41. Hicks JK, Bahn YS, Heitman J. Pde1 phosphodiesterase modulates cyclic AMP levels through a protein kinase A-mediated negative feedback loop in Cryptococcus neoformans. Eukaryot Cell. 2005; 4(12):1971-1981.
42. Lee A, et al. Survival defects of Cryptococcus neoformans mutants exposed to human cerebrospinal fluid result in attenuated virulence in an experimental model of meningitis. Infect Immun. 2010; 78(10):4213-4225.